Real-world Comparative Effectiveness of Anti-EGFRs with Doublet Chemotherapy Versus Doublet Chemotherapy with or without Bevacizumab in Firstline Among RAS/RAF Wild-type, non-dMMR/MSI High mCRC Patients with Left-sided Primary Tumors in the Flatiron Health CRC Enhanced Datamart (20240215)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000470
• EU PAS number:
  EUPAS1000000470
• Study ID:
  1000000470
• Official title and acronym:
  Real-world Comparative Effectiveness of Anti-EGFRs with Doublet Chemotherapy Versus Doublet Chemotherapy with or without Bevacizumab in Firstline Among RAS/RAF Wild-type, non-dMMR/MSI High mCRC Patients with Left-sided Primary Tumors in the Flatiron Health CRC Enhanced Datamart (20240215)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Ongoing

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned: 15/11/2024

Study start date

Planned: 29/01/2025

Actual: 29/01/2025

Data analysis start date

Planned: 03/03/2025

Actual: 03/03/2025

Date of final study report

Planned: 01/12/2025

Sources of funding

Pharmaceutical company and other private sector 

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable